This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Navigating payer challenges for rare disease treatments requires innovative approaches to evidence generation and pricing strategies. Our Life Sciences practice is dedicated to providing tailored solutions to help maximize value and drive towards equitable access to life-saving treatments.
China’s Rare Disease Catalogue (RDC) plays a growing role in shaping awareness, investment, and access to therapies for rare diseases in China.
“We are pleased to welcome Phoebe and Chris to CRA,” said Paul Maleh, President and Chief Executive Officer of Charles River Associates. “They are seasoned...
Abhishek Kumar presents his poster titled “Top Trends Affecting the Vaccines Market and their Implications on Access Policy and Public Health...
CRA is a proud sponsor of the conference focusing on the intersection of intellectual property and the biopharmaceutical industry, and will explore the law,...
